Edition:
India

People: Assembly Biosciences Inc (ASMB.OQ)

ASMB.OQ on NASDAQ Stock Exchange Global Select Market

15.77USD
8:52pm IST
Change (% chg)

$0.09 (+0.57%)
Prev Close
$15.68
Open
$15.70
Day's High
$16.00
Day's Low
$15.66
Volume
11,049
Avg. Vol
90,229
52-wk High
$48.62
52-wk Low
$13.13

Altig, Anthony 

Mr. Anthony E. Altig is an Independent Director of Assembly Biosciences Inc. Mr. Altig joined our Board in January 2012. From 2008 to December 2017, Mr. Altig was the Chief Financial Officer of Biotix Holdings, Inc., a company that manufactures microbiological consumables, which was acquired by Mettler Toledo in September 2017. From 2004 to 2007, Mr. Altig served as the Chief Financial Officer of Diversa Corporation (subsequently Verenium Corporation), a public company developing specialized industrial enzymes. Prior to joining Diversa, Mr. Altig served as the Chief Financial Officer of Maxim Pharmaceuticals, Inc., a public biopharmaceutical company. In addition, Mr. Altig serves as a director and chairman of the audit committee for TearLab Corporation (formerly OccuLogix, Inc.), a publicly traded eyecare technology company. He formerly served as a director of MultiCell Technologies, Inc. and Optimer Pharmaceuticals, Inc., a pharmaceutical company, which was a public company until its acquisition by Cubist Pharmaceuticals, Inc. in October 2013. Mr. Altig received his B.B.A. in business from the University of Hawaii at Manoa and is a Certified Public Accountant (inactive). Among other experiences, qualifications, attributes and skills, Mr. Altig’s extensive management experience and financial expertise, as well as his experience serving on the boards of directors of several public pharmaceutical and healthcare companies, led to the conclusion of our Board that he should serve as a director of the Company in light of our business and structure.

Basic Compensation

Total Annual Compensation, USD 47,500
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 135,371
Fiscal Year Total, USD 182,871

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --